Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Max 4 meds. Sources include DailyMed labels; verify against official labeling. On small screens the table defaults to a compact view—use “Show all columns” to view everything (scroll horizontally).
Compare 3/4 selected
| Medication | Dosing highlights | Risk flags | LAI options |
|---|---|---|---|
Initiation typically follows a “confirm oral tolerability” approach: establish an effective oral dose, administer the first injection, and continue a short oral overlap per label while depot concentrations rise.
Maintenance is usually once monthly; dose selection (e.g., 300 mg vs 400 mg) is individualized to response, tolerability, and interaction profile. |
| Monthly (q4wk) | |
aripiprazole lauroxilLong-acting injectable antipsychoticBrands: ARISTADA, ARISTADA INITIO View labelExact | Initiation requires bridging: either a multi-week oral aripiprazole overlap or a one-day initiation strategy using Aristada Initio per label.
Maintenance interval depends on strength (monthly, every 6 weeks, or every 2 months in labeled schedules). Injection site and technique vary by dose and product instructions. |
| q4–8wk (varies by strength) |
paliperidone palmitateLong-acting injectable antipsychoticBrands: INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA View labelExact | PP1M initiation uses a labeled loading sequence (deltoid injections on day 1 and day 8) followed by monthly maintenance. Oral overlap is not typically required after the loading sequence. |
| Monthly / q3mo / q6mo |
2 more columns available — use “Show all columns” above.5 more columns available — use “Show all columns” above.6 more columns available — use “Show all columns” above.